Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

[1]  S. Kılıçkap,et al.  Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report , 2022, Cureus.

[2]  T. Wilson,et al.  MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC , 2022, Thoracic cancer.

[3]  Kristen L Jones,et al.  Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors , 2021, Molecular Cancer Therapeutics.

[4]  P. Ma,et al.  Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy , 2019, Journal of Hematology & Oncology.

[5]  G. Ferretti,et al.  Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Drilon,et al.  Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 , 2019, Annals of Oncology.

[7]  J. Ahn,et al.  Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer , 2019, Investigational New Drugs.

[8]  R. Camidge,et al.  Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Meijuan Huang,et al.  Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .